
New phone system at TWINCORE
Some extension numbers have changed.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Ilan S, Bartsch Y, Jung W, Kliuchnikov E, Roy V, Bonifer R, Walker-Sperling V, Borducchi E, Nkolola J, Lauffenburger D, Stieh D, Barouch D, Julg B
Koeken V, Nissen T, Birk N, Boahen C, van Crevel R, Kumar V, Li Y, Aaby P, Benn C, Netea M
Vadaq N, Groenendijk A, Dos Santos J, Mehta K, Wit F, Vos W, Blaauw M, van Eekeren L, Lambrechts L, Rutsaert S, Nelwan E, Xu C, Joosten L, de Mast Q, Matzaraki V, van Lunzen J, Rokx C, Verbon A, Netea M, Vandekerckhove L, van der Ven A
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
The project investigates the factors that determine the species barrier mechanism of HCV and make it impossible to study the infection in animal models. The aim is to use genetic screening systems to develop in vivo models for vaccine research.
Thanks to high-throughput sequencing, genome sequences of hundreds of bacterial strains can be analyzed efficiently, revealing differences of up to 60 % in gene content, as in E. coli. With the help of machine learning, we want to better predict the functions of accessory genes and decipher their contribution to survival in specialized niches.

